Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can smart fluid monitoring improve robotic prostatectomy outcomes?

NCT ID NCT07806539

Knowledge-focused Sponsor: Antalya Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study looks at how giving fluids during robotic prostatectomy affects patient outcomes. It compares two approaches: one guided by a special monitor (LiDCO) that tracks blood flow in real time, and the other using standard clinical judgment. The researchers will measure the total fluids given and track blood lactate levels and vasopressor use to see if the guided approach leads to better results. The study includes 48 men aged 18 to 80 undergoing this surgery, and it does not assign treatments, just observes what happens in routine practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LiDCO-guided goal-directed fluid therapy versus conventional fluid therapy
What this could lead to
If the LiDCO-guided approach reduces excess fluids and improves recovery, it could become a standard for robotic prostatectomy, leading to fewer complications and shorter hospital stays.
What could go wrong
This is an observational study with only 48 participants, so it cannot prove cause and effect. Results may not apply to other surgeries or hospitals, and the LiDCO monitor has its own limitations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

48 people

The number who actually took part.

Started

Feb 2026

Finished

Aug 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult male patients aged 18-80 years with prostate cancer who are scheduled for elective robotic radical prostatectomy at Antalya Training and Research Hospital and meet the study eligibility criteria will be prospectively enrolled after providing written informed consent.

Ages

18 to 80 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patients aged 18 to 80 years * Patients scheduled for elective robotic radical prostatectomy * American Society of Anesthesiologists physical status I-III * Patients who provide written informed consent Exclusion Criteria: * Refusal to participate in the study * Cardiac rhythm disturbances * Severe left ventricular dysfunction, defined as ejection fraction \<40% * Severe valvular heart disease or active heart failure * Chronic renal failure, dialysis dependency, or preoperative creatinine \>2 mg/dL * Hemoglobin \<8 g/dL * Pre-existing hematological conditions requiring planned blood transfusion * Body mass index \>40 kg/m² * Major peripheral vascular disease * Implanted pacemaker or implantable cardioverter-defibrillator * Chronic obstructive pulmonary disease * Conditions associated with increased intra-abdominal pressure * Emergency surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer Robotic radical prostatectomy

Contacts and locations

Locations

  • Antalya Training and Research Hospital

    Antalya, 07070, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.